Clinical-stage biotechnology company developing engineered regulatory T-cell (Treg) therapies for severe autoimmune and inflammatory diseases
Clinical-stage biotechnology company developing engineered regulatory T-cell (Treg) therapies for severe autoimmune and inflammatory diseases. Its tissue-specific cell therapy pipeline includes programs for progressive multiple sclerosis and type 1 diabetes.